Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Hepatocyte levels of CD73 contribute to Mallory-Denk body formation.

French S.

Hepatology. 2014 Aug;60(2):767. doi: 10.1002/hep.26953. Epub 2014 Jun 18. No abstract available.

PMID:
24285131
2.

CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation.

Snider NT, Griggs NW, Singla A, Moons DS, Weerasinghe SV, Lok AS, Ruan C, Burant CF, Conjeevaram HS, Omary MB.

Hepatology. 2013 Nov;58(5):1790-800. doi: 10.1002/hep.26525. Epub 2013 Aug 26.

3.

Reply: To PMID 23729294.

Snider NT, Omary MB.

Hepatology. 2014 Aug;60(2):767-8. doi: 10.1002/hep.26952. Epub 2014 Jun 18. No abstract available.

4.

Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation.

Kwan R, Hanada S, Harada M, Strnad P, Li DH, Omary MB.

FASEB J. 2012 Jun;26(6):2318-26. doi: 10.1096/fj.11-198580. Epub 2012 Feb 23.

5.

Ecto-5'-nucleotidase (cd73)-dependent and -independent generation of adenosine participates in the mediation of tubuloglomerular feedback in vivo.

Huang DY, Vallon V, Zimmermann H, Koszalka P, Schrader J, Osswald H.

Am J Physiol Renal Physiol. 2006 Aug;291(2):F282-8. Epub 2006 Mar 8.

6.

CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation.

Zernecke A, Bidzhekov K, Ozüyaman B, Fraemohs L, Liehn EA, Lüscher-Firzlaff JM, Lüscher B, Schrader J, Weber C.

Circulation. 2006 May 2;113(17):2120-7. Epub 2006 Apr 24.

7.

Opportunities and challenges for anti-CD73 cancer therapy.

Zhang B.

Immunotherapy. 2012 Sep;4(9):861-5. doi: 10.2217/imt.12.83. No abstract available.

8.

Deletion of CD73 promotes dyslipidemia and intramyocellular lipid accumulation in muscle of mice.

Burghoff S, Flögel U, Bongardt S, Burkart V, Sell H, Tucci S, Ikels K, Eberhard D, Kern M, Klöting N, Eckel J, Schrader J.

Arch Physiol Biochem. 2013 May;119(2):39-51. doi: 10.3109/13813455.2012.755547. Epub 2013 Feb 11.

PMID:
23398498
9.

Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors.

Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK.

Circulation. 2007 Mar 27;115(12):1581-90. Epub 2007 Mar 12.

10.

CD73 mediates adhesion of B cells to follicular dendritic cells.

Airas L, Jalkanen S.

Blood. 1996 Sep 1;88(5):1755-64.

11.

Cardiovascular ecto-5'-nucleotidase: an end to 40 years in the wilderness?

Olsson RA.

Circ Res. 2004 Oct 15;95(8):752-3. No abstract available.

12.

IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation.

Niemelä J, Henttinen T, Yegutkin GG, Airas L, Kujari AM, Rajala P, Jalkanen S.

J Immunol. 2004 Feb 1;172(3):1646-53.

13.

Ecto-5' nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy.

Hasegawa T, Bouïs D, Liao H, Visovatti SH, Pinsky DJ.

Circ Res. 2008 Dec 5;103(12):1410-21. doi: 10.1161/CIRCRESAHA.108.180059. Epub 2008 Nov 13.

14.

Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury.

Eckle T, Füllbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, Eltzschig HK.

J Immunol. 2007 Jun 15;178(12):8127-37.

15.

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemelä J, Laurila JP, Elima K, Jalkanen S, Salmi M.

Eur J Immunol. 2011 May;41(5):1231-41. doi: 10.1002/eji.201041292.

16.

Human T cell activation. Synergy between CD73 (ecto-5'-nucleotidase) and signals delivered through CD3 and CD2 molecules.

Massaia M, Perrin L, Bianchi A, Ruedi J, Attisano C, Altieri D, Rijkers GT, Thompson LF.

J Immunol. 1990 Sep 15;145(6):1664-74.

PMID:
1975259
17.

CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73.

Airas L, Hellman J, Salmi M, Bono P, Puurunen T, Smith DJ, Jalkanen S.

J Exp Med. 1995 Nov 1;182(5):1603-8.

18.

Control of IFN-alphaA by CD73: implications for mucosal inflammation.

Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP.

J Immunol. 2008 Mar 15;180(6):4246-55.

20.

Sensitivity and specificity of in situ proximity ligation for protein interaction analysis in a model of steatohepatitis with Mallory-Denk bodies.

Zatloukal B, Kufferath I, Thueringer A, Landegren U, Zatloukal K, Haybaeck J.

PLoS One. 2014 May 5;9(5):e96690. doi: 10.1371/journal.pone.0096690. eCollection 2014.

Supplemental Content

Support Center